Island Pharmaceuticals Ltd (ASX:ILA) has now dosed all eight subjects in the second cohort of its ISLA-101 Single Ascending Dose (SAD) study. ISLA-101 is a well-known drug candidate being repurposed for the prevention and treatment of dengue and other mosquito-borne diseases.
Of the second cohort of eight subjects, three cohorts of healthy subjects will receive escalating doses of ISLA-101.
The SAD study aims to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus
Dosing of the second cohort follows confirmation from the Safety Review Committee that ISLA-101 was safe and tolerable when the first dose was received by the first cohort of healthy subjects.
Island Pharmaceuticals CEO Dr David Foster said: “We are pleased that ISLA-101 demonstrated good tolerability in the first dose escalation phase and we are now excited to have progressed the dosing of the whole second cohort of subjects.
"We are on track to complete the third and final cohort and have data read-outs in early 2024, which will then inform our planned Phase 2a PEACH clinical trial.”
The Single Ascending Dose study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney by Contract Research Organisation, Beyond Drug Development. The study results are expected in early 2024.